Literature DB >> 36203613

A novel CARD11 germline mutation in a Chinese patient of B cell expansion with NF-κB and T cell anergy (BENTA) and literature review.

Peiwei Zhao1, Yanqiu Hu1, Dongming Sun2, Qingjie Meng3, Lei Zhang1, Xiankai Zhang1, Li Tan1, Yong Zhang2, Yan Ding4, Xuelian He1.   

Abstract

Germline gain-of-function (GOF) mutations in the CARD11 gene lead to a rare primary immunodeficiency disease known as B cell expansion with NF-κB and T cell anergy (BENTA). Affected patients present with a polyclonal expansion of B cells, lymphadenopathy, and splenomegaly. Herein, we report a novel germline in-frame three base-pair deletion (c.1030_1032del, p.K344del) in the CARD11 gene in a patient with atypical BENTA, presenting with a recurrent fever and B cell lymphocytosis. This mutation was inherited from his mother, who is clinically asymptomatic and had a recurrent respiratory tract infection in her childhood. In vitro functional analysis demonstrated that this variant decreased the expression level of the CARD11 protein and activated the NF-κB signal pathway, leading to a higher expression of several NF-κB target gene transcripts in HCT116 cells transfected with mutant CARD11 (K344del-CARD11) as revealed by RNA sequencing analysis. To our knowledge, only 23 BENTA patients have been identified and carried seven distinct GOF mutations in CARD11. The clinical manifestations of patients are highly heterogeneous and there was no significant correlation between genotype and phenotype. In summary, we identified a novel in-frame three base-pair deletion that may be responsible for the pathogenesis of atypical BENTA in a Chinese family. Our study expands the mutational spectrum of the CARD11 gene and may be helpful in the understanding of diseases caused by CARD11 mutations and the clinical management of BENTA.
Copyright © 2022 Zhao, Hu, Sun, Meng, Zhang, Zhang, Tan, Zhang, Ding and He.

Entities:  

Keywords:  BENTA; CARD11; NF-κB; gain-of-function; lymphocytosis

Mesh:

Substances:

Year:  2022        PMID: 36203613      PMCID: PMC9530255          DOI: 10.3389/fimmu.2022.943027

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   8.786


Introduction

B cell expansion with NF-κB and T cell anergy (BENTA) (OMIM 616452) was first reported in 2012 and is a rare primary immunodeficiency disease. Patients present with persistent B cell lymphocytosis in early childhood, usually accompanied by lymphadenopathy and splenomegaly (1, 2). BENTA is caused by heterozygous germline gain of function (GOF) mutations in the CARD11 gene, which encodes a caspase recruitment domain-containing protein (CARD11, also known as CARMA1) (3). The CARD11 is a lymphocyte-specific scaffolding protein and acts as a critical signal transducer from the cell surface antigen receptor (AgR) in B or T cells to the cytoplasmic IκB kinase (IKK). This in turn activates the canonical NF-κB pathway (4). An overactive NF-κB pathway is associated with B cell malignancy (5). Somatic mutations in CARD11 have been reported in different cancers, especially in diffuse larger B cell lymphoma (DLBCL) (6). Germline CARD11 mutations have been associated with several primary immune disorders, including immunodeficiency 11A (OMIM 615206) (7), immunodeficiency with atopic dermatitis (OMIM 617638) (8), and BENTA caused by heterozygous GOF mutations (3). These immune disorders were caused by bi-allelic loss-of-function (LOF) mutations, heterozygous dominant negative, and GOF mutations, respectively. To date, 23 patients with BENTA have been identified to carry seven distinct GOF mutations, including C49Y, G123S, G123D, G126D, E134G, H234Ldel235-8, and K215del (3, 9–19). These mutations are located in the CARD, LATCH, or CC domains of CARD11. In this study, a germline heterozygous mutation (c.1030_1032del, p.K344del) has been identified in the CARD11 gene in a Chinese boy with recurrent fever and B cell lymphocytosis. This mutation was inherited from his mother who had a recurrent respiratory tract infection in childhood and is clinically asymptomatic. Our functional study suggests that this mutation resulted in an overactive NF-κB in vitro. In addition, we review the literature and summarize the clinical phenotypes and genotypes of all BENTA patients.

Material and methods

Patient and samples

This work has been approved by the ethics committee of Wuhan Children’s Hospital, Tongji Medical College, and Huazhong University of Science & Technology, and informed consent was obtained from the parents of the patient. The patient was recruited in this study because of recurrent fever. After 3ml of peripheral blood was collected from both this patient and his parents, genomic DNA and RNA were extracted by using the MicroElute Genomic DNA Kit (OMEGA Bio-tek) and Trizol reagent (Invitrogen), respectively.

Whole exome sequencing

Trio WES was conducted with the help of the third-party medical testing laboratory (Chigene (Beijing) Translational Medical Research Center. China), and subsequent bioinformatic analysis was done as described previously in our laboratory (20). The candidate gene variants were validated by Sanger sequencing in this patient and his parents. The primers sequence are as follows: CARD11-F: CAA CAG TCA GAT AGT CGG TTCC; CARD11-R: GAC AAA ACA CTC TGA AGG AGCC. The conservation analysis of the protein amino acid was conducted using MEGA software.

CARD11 gene plasmid construction and cell transfection

Site-directed mutagenesis was performed to generate K344del-CARD11 using specific primers for linear amplification, followed by DpnI digestion of methylated DNA. Positive colonies were subjected to sequencing analysis to verify the successful deletion of the guide sequence. The wildtype CARD11 plasmid (WT-CARD11) and positive control (C49Y-CARD11) were included as described previously (16). After being cultured in DMEM supplemented with 10% fetal bovine serum (Gibco, Thermo Fisher Scientific) for 24 hours, HCT116 cells were transfected with 2 μg plasmids (pcDNA3.1, WT, C49Y, WT+K344del, and K344del using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s instructions.).

Western blot

The detailed experimental protocol is similar to our previously published article (16). Cells were lysed in NP-40 lysis buffer on ice, and then centrifugated at 12000rpm for 10 minutes at 4°C. Cell nucleoprotein was extracted using NE-PER™ Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific). The extracted protein was separated by SDS-PAGE and WB was used to detect the expression level of related proteins with the following antibodies: anti-CARD11(Proteintech, 21741-1-AP), anti-NF-κB p65(Cell Signaling Technology, #8242), lamin B (Santa cruz, sc-377000), and GAPDH(Proteintech, 60004-1-Ig).

Immunofluorescence

Cells cultured in a confocal dish were fixed for 15 minutes with 3% paraformaldehyde and then permeabilized for 15 minutes in 0.1% Triton X-100/PBS. After blocking in a 3% BSA buffer, cells were incubated with the CARD11 antibody (Proteintech, 21741-1-AP) for 90 minutes. Cells were washed in PBS and then incubated with a secondary antibody conjugated to Alexa Fluor 488 (Invitrogen) at normal temperature. After washing three times, DAPI was added to the cell culture dish. Fluorescent images were obtained on a confocal microscope (Leica Stellaris 5).

IgH rearrangement analysis

DNA was extracted from peripheral blood using MicroElute Genomic DNA Kit (OMEGA Bio-tek). PCR was performed using fluorescent-labeled primers to the VH framework region (FR II) and joining region(JH) of the IgH gene. The amplification products were separated by capillary electrophoresis and analyzed on Genetic Analyzer (3500DX, ABI) using GeneMapper software version 5.0 (Applied Biosystems).

Luciferase reporter assays

HCT116 cells were plated in 12-well culture plates (3 × 105 cells/well) for 12h. The cells were then co-transfected with either 500 ng of pcDNA3.1+, CARD11-WT, and -C49Y- -K344del, 300 ng of pNFκB-luc (Bayotime, China) containing NF-κB binding motifs, or 100 ng of pRL-TK vector as a control (Promega, Madison, WI). After 36h, cells are lysed in lysate buffer and then analyzed for luciferase activity using the Dual-Luciferase reporter Assay System (Promega, Madison, WI). Three independent experiments were performed to assess luciferase activity.

RNA-seq analysis

The experimental protocol was carried out as described previously (16). RNA was isolated from HCT116 cells transfected with CARD11-K344del or CARD11-WT plasmids, respectively. After constructing cDNA libraries, sequencing analysis was carried out on an Illumina sequencer instrument. Gene expression was calculated as transcripts per million (TPM) mapped reads by using the TopHat alignment program with redundant reads removed, and the expression values were normalized by using . The raw data was submitted to the SRA database (SUB11737083).

Quantitative PCR analysis

After the cDNA was generated from the total RNA isolated from HCT116 cells transfected with wild-type and mutant CARD11 gene, respectively, a quantitative PCR experiment was performed on ABI 7500 instrument (Applied Biosystems, USA) using SYBR green preMix Taq Kit (TAKARA, Dalian). Single amplicons of predicted size were confirmed by agarose gel electrophoresis analysis. Raw data was calculated as an average of three independent experiments. ACTIN was included as an internal control.

Statistics methods

Graphpad Prism 5 (Graphpad software, USA) was used for statistical analyses. The Student’s t-test was used to compare two groups, a one-way analysis of variance (ANOVA) was used to compare one variable among three or more groups, and statistical significance is indicated by a P-value (*P<0.05, **P<0.01, ***P<0.001). All experiments were performed in duplicates and repeated three times, and data are described as the mean ± SD.

Results

Case presentation

The patient was a 13-month-old male of Chinese descent who was referred for genetic evaluation because of unexplained recurrent fever. He is the only child born to healthy non-consanguineous parents without familial history of genetic diseases. There were no complications during pregnancy and no obvious abnormality was found at birth. When he was 7 months old, the patient presented with a recurrent fever (8 times within two months), with a maximum temperature of 39.2°C, and a persistent upper respiratory tract infection. He had a small rash on his face after the fever. The rest of his physical examination was unremarkable and he had no palpable lymph nodes. Clinical laboratory examination showed the proportion of lymphocytes (84.8%, normal range 40-70%) increased significantly with normal morphological characteristics and normal total white blood cell counts (9.67*109/L). The CD19+ B cell population was expanded at presentation (3,432 cells/μL, normal range 240-1,317cells/μL), and the proportion of NK cells was decreased (3.03%). The patient did not receive any special treatment, other than immunization and other symptomatic treatments. Over the next six months, the patient still had periodic fever episodes occurring every 8 days and lasting for 2-3 days. When the patient was 13 months old, he was admitted to our hospital again because of recurrent fever. The summary of routine blood tests and immunological investigations is provided in . Initial blood analyses showed the proportion of lymphocyte cells and CD19+ B-cells were increased, and the hemoglobin level was decreased (90g/L, normal range 110-149g/L). A bone marrow biopsy showed hyperplastic anemia ( ). An IgH rearrangement experiment indicated that the patient’s B cells were polyclonal ( ). An abdominal CT scan showed multiple mesenteric lymphadenopathies and an ultrasound examination revealed a normal spleen size and an accessory spleen at the hilum.
Table 1

Clinical characteristics of the patient.

Clinical manifestationDetection resultReference value
Age/sex13 month/male
Age of onset4 month
Clinical manifestationRecurrent fever;Hypogammaglobulinemia
Glutamic-pyruvic transaminase (U/L)149-60
Aspartate aminotransferase (U/L)3810-50
Ferritin (ng/ml)11.3422-322
WBC(10^9/L)6.215.5-12
RBC(10^12/L)4.743.7-5.3
PLT(10^9/L)506100-378
HGB(g/L)90110-149
Lymphocytes (%)72.640-70
CD3+ T lymphocytes (n/ul)5196805-4459
CD3+%46.1638.56-70.06
CD4+ T lymphocytes (n/ul)2526345-2350
CD4+%22.8914.21-36.99
CD8+ T lymphocytes (n/ul)2145314-2080
CD8+%19.4313.24-38.53
CD 19+ B lymphocytes (n/ul)5283240-1317
CD 19+ %46.0810.86-28.03
CD 16 + 56+ NK cells (n/ul)511210-1514
CD 16 + 56+ %4.457.92-33.99
s.IgG (g/L)4.703.48-7.01
s.IgA (g/L)< 0.260.28-1.08
s.IgM (g/L)0.260.42-1.73
Triglycerides (mmol/L)1.820.32-1.46
Bone marrow cell morphologymicrocytic hypochromic anemia
Figure 1

Characterization of our patient with CARD11 gene mutation and conserved features of the CARD11 protein. (A) Bone marrow smear from the patient showing microcytic hypochromic anemia; (B) Result of IgH rearrangement of our patient; (C) Pedigrees of this family and sanger sequencing of CARD11 mutation in this family; (D) Aligned amino acid sequence at this mutation among different species. The position at residue 344 is noted by a gray bar and highly conserved throughout all indicated species; (E) Scheme of the distribution of the CARD11 gain-of-function mutations, and the mutation noted in red was reported in this study. Gain of function mutations are highlighted in red, dominant negative mutations are in blue, and loss of function mutations are in black.

Clinical characteristics of the patient. Characterization of our patient with CARD11 gene mutation and conserved features of the CARD11 protein. (A) Bone marrow smear from the patient showing microcytic hypochromic anemia; (B) Result of IgH rearrangement of our patient; (C) Pedigrees of this family and sanger sequencing of CARD11 mutation in this family; (D) Aligned amino acid sequence at this mutation among different species. The position at residue 344 is noted by a gray bar and highly conserved throughout all indicated species; (E) Scheme of the distribution of the CARD11 gain-of-function mutations, and the mutation noted in red was reported in this study. Gain of function mutations are highlighted in red, dominant negative mutations are in blue, and loss of function mutations are in black.

Identification of germline CARD11 mutation

In order to determine the cause of the patient’s recurrent fever and rule out the genetic disorder, a trio WES was conducted. Bioinformatic analysis was performed to identify candidate variants according to filtering strategy and the pathogenicity of identified variants was assessed as described previously (20). After analysis, a heterozygous in-frame three base-pair deletion mutation (c.1030_1032del, p.K344del) was identified in the CARD11 gene (NM_032415), and a Sanger sequencing analysis showed this mutation was inherited from the patient’s mother ( ). The mutated site is conserved among different species ( ). Interestingly, similar to most other BENTA-associated variants, the K344del variant was located in CC domain ( ). The germline variant has not been listed in the Clinvar, ExAC, gnoMAD, or dbSNP databases, while the somatic variant was included in the Catalogue of Somatic Mutations in Cancer (COSMIC) in a patient with diffuse large B cell lymphomas (DLBCL). We submitted this variant to the Clinvar database (https://submit.ncbi.nlm.nih.gov/subs/clinvar_wizard/SUB11735856/overview). Given that the K344del variant was inherited from the mother, we also made a detailed inquiry into whether the mother had similar symptoms. The mother, who is clinically asymptomatic, told us that she had a recurrent respiratory tract infection in childhood. The clinical laboratory examinations, including the total white blood cell counts, the proportion of lymphocytes, CD19+ B cell population, and the proportion of NK cells were in normal ranges.

K344del spontaneously aggregates and constitutively activates NF-κB

To examine the effect of K344del, K344del-CARD11, positive control C49Y-CARD11, WT-CARD11, and empty plasmids were individually transfected into HCT116 cells. Our results showed that K344del significantly decreased the expressions of both gene and protein of CARD11 ( ). Similar to the positive control (C49Y), K344del resulted in CARD11 protein aggregation into large complexes, whereas WT-CARD11 dispersed throughout the cytoplasm ( ). In addition, p65 protein was significantly increased in mutant CARD11 compared to wild-type CARD11( ). NF-κB activation was also examined by measuring pNF-kB-luc reporter gene expression in HCT116 cells transfected with pcDNA3.1(+), CARD11-WT, -K344del, or -C49Y plasmids. As shown in ( ), the luciferase activity in cells with mutated K344del-CARD11 was significantly higher than that in cells with CARD11-WT. Taken together, overexpression of K344del drives NF-κB activation. To mimic the proband’s state, K344del CARD11 was co-transfected at a 1:1 ratio with wild-type CARD11, and a similar change in the NF-κB signaling pathway was also detected in a heterozygous state by both western blot and luciferase reporter gene experiments ( ). Given that the cells only transfected with wild-type CARD11 had a higher level of CARD11 compared to those with only K344del-CARD11, a more appropriate ratio of WT-CARD11 to K344del-CARD11 used for transfection was determined to rule out the effect of wild-type CARD11. We found that the expression levels of wild-type and mutant CARD11 were comparable when the ratio of wild-type to mutant plasmid was 1 to 4 ( ). In the heterozygous state, similar to the proband, the activity of NF-κB luciferase was elevated significantly in the cells carrying the K344del plasmids in vitro ( ), suggesting that the mutation does not have a dominant negative effect. In addition, we also noted that several NF-κB target gene transcripts had higher expressions in HCT116 cells transfected with mutated CARD11 compared to that of wild-type CARD11 detected by RNA-seq ( ).
Figure 2

Expressions and Distribution of CARD11-WT and K344del in HCT116 cells. Expressions of RNA and protein of mutant CARD11 and its controls (A, B, respectively); (C) Distribution of CARD11-WT, -C49Y, and –K344del in HCT116 cells investigated by immunofluorescence.

Figure 3

Functional analysis of K344del mutation in HCT116 cells. (A) The expression levels of CARD11, NF-κB p65 in HCT116 cells transfected with wildtype or mutant CARD11 in whole cell lysates and nuclear lysates, GAPDH and Lamin B serve as a loading control; (B) The activity of NF-κB-dependent luciferase of cell extracts from each sample was measured and recorded as a fold increase compared to control cells with WT-CARD11 plasmid. (C) The expression levels of CARD11 in different ratios of plasmid transfection. (D) The luciferase activity of cells transfected with mutants was increased in the case of consistent expression levels. The results from three independent experiments are described as the mean + standard deviation (*P < 0.05; **P < 0.01, ***P < 0.001). (E) Heat map of differentially expressed genes involved in NF-κB signal pathway between WT and K344del by RNA-seq analysis in HCT116 cells, the color scales of heatmap refer to Log2TPM.

Expressions and Distribution of CARD11-WT and K344del in HCT116 cells. Expressions of RNA and protein of mutant CARD11 and its controls (A, B, respectively); (C) Distribution of CARD11-WT, -C49Y, and –K344del in HCT116 cells investigated by immunofluorescence. Functional analysis of K344del mutation in HCT116 cells. (A) The expression levels of CARD11, NF-κB p65 in HCT116 cells transfected with wildtype or mutant CARD11 in whole cell lysates and nuclear lysates, GAPDH and Lamin B serve as a loading control; (B) The activity of NF-κB-dependent luciferase of cell extracts from each sample was measured and recorded as a fold increase compared to control cells with WT-CARD11 plasmid. (C) The expression levels of CARD11 in different ratios of plasmid transfection. (D) The luciferase activity of cells transfected with mutants was increased in the case of consistent expression levels. The results from three independent experiments are described as the mean + standard deviation (*P < 0.05; **P < 0.01, ***P < 0.001). (E) Heat map of differentially expressed genes involved in NF-κB signal pathway between WT and K344del by RNA-seq analysis in HCT116 cells, the color scales of heatmap refer to Log2TPM.

Literature review of patients with BENTA

A literature review of BENTA cases was conducted by searching for all cases published from 2012 (BENTA was first reported in 2012) to 2021 with the keywords “CARD11 gene” and “B cell expansion with NF-κB and T cell anergy “. The database included Pubmed, Medline, and Clinvar et al. We reviewed 12 articles which included 23 cases with BENTA, and the clinical features of these patients were summarized in .
Table 2

Literature review of the clinical features of BENTA patients.

PatientsAge/sexlymphadenopathysplenomegalylymphocytosisInfectionsIgG(g/L)IgA(g/L)IgM(g/L)IgE(U/mL)CD19+BCD3+TCD4+TCD8+TCD16+CD56CARD11
P1[13]8M/FNDEBV6.90.060.4331246060875155272303921G123S
P2[13]2M/MSinopulmonary323.093.89119012027412324051374687G123D
P3[13]9M/FSinopulmonary11.80.070.4335.626150549029061938646C49Y
P4[13]3Y/FSinopulmonary,otitis media12.70.081.454.451946134294026834C49Y
P5[3]55/Mflu-like symptoms, pleuraleff usion.hypogammaglobulinemialowlowE134G
P6[3]13Y/FNDfrequent upper respiratory tract, throat, and middle ear infections. She also had occasional sinus infectionshypogammaglobulinemialow serum IgM470322871202697268E134G
P7[3]11Y/Frecurrent tonsillitis and otitis media.low serum IgM471024641282885325E134G
P8[3]6Y/Fbronchitis, bilateral pneumonia with Streptococcuspneumoniae bacteremia81056229138442301061G123S
P9[10]22M/Fcoryzal symptoms and intermittent diarrhea9.460.580.7392.67160363024807600460K215del
P10[11]80Y/FNDNDNDsuffered from recurrent warts, shingles and sinusitisH234LΔ235-8
P11[11]57Y/Ffrequent otitis externa andcolds; persistent onychomycosis11.352.550.371661221821074970306H234LΔ235-8
P12[11]32Y/Mmultiple warts on hands, EBV11.291.610.3937.5106620071328535197H234LΔ235-8
P13[11]6Y/MNNpustular psoriasis, pneumonia12.040.720.14136160219611291507133H234LΔ235-8
P14[12]59Y/Msuspected viral meningitis, pneumonia, childhood360015001300150G123S
P15[14]20Y/FNDfever, urticariafollowed by septic infection5.550.270.62~5000~580~300~220G123S
P16[15]12Y/Motitis media, febrile episodes, episodes of sinusitis and bronchitis482625522265118771270G123D
P17[16]8M/Ma persistent upperrespiratory tract infection, fever with splenomegaly18.60.110.5228821624648932372G126D
P18[19]12Y/Frespiratory tract infections, cervical lymphadenopathy, and tonsillitis5.011.690.371higher than normalG123S
P19[17]43Y/FNDNDEBV114229896C49Y
P20[18]16Y/FNDupper respiratory tract7.560.270.752801999592342283C49Y
P21[18]18Y/Mrecurrent URT infections, otitis media,9.930.61.38190016721102418228C49Y
P22[18]51Y/FNNN11.131.390.32912798513152190C49Y
P23[9]13Y/Fadenopathy. recurrent otitis medianormalnormalnormalhigher than normalC49Y
This work13M/MNNRecurrent fever;hypogammaglobulinemia4.700.260.265283519625262145511K344del

ND, no data.

Literature review of the clinical features of BENTA patients. ND, no data. Among the 24 BENTA patients (17 families), there were 9 male patients and 15 female patients, aged from 2 months to 80 years. The main clinical manifestations in the patients were lymphocytosis, splenomegaly, lymphadenopathy, recurrent infection, and recurrent fever. The clinical presentation and course are highly variable, from severe lymphocytosis and dying at a very young age (Tab, P1, P3, P4), to repeated infection in childhood and clinically asymptomatic in adulthood (P22). A total of 7 germline GOF mutations (C49Y, G123S, G123D, G126D, E134G, K215del, and H234Ldel235-8) have been reported (8–13), and these mutations are located in the CARD, LATCH, or CC domains of CARD11 ( ). The K344del reported in this study is located in the CC domain. There was no significant correlation between genotype and phenotype. For instance, Buchbinder reported that 3 patients carrying C49Y mutation presented with milder clinical symptoms, while patients (P3 and P4) with this mutation died at a young age (13). All these variants, except E134G and H234Ldel235-8, were included in the COSMIC database and are identified as somatic mutations in patients with DLBCL, chronic lymphocytic leukemia, or lymphoma. This information indirectly indicates that BENTA patients with GOF mutation are at a high risk of developing lymphoma or leukemia, and some BENTA patients had developed lymphoma or B-ALL in adulthood (3, 11).

Discussion

In this work, we have reported on a 13-month-old patient with B cell lymphocytosis, persistent recurrent fever, and upper respiratory tract infection but without lymphadenopathy or splenomegaly. The WES revealed a novel germline in-frame three base-pair deletion, c.1030_1032del(p.K344del) in the CARD11 gene, which was associated with BENTA, severe combined immune deficiency, and severe atopic disease. According to the patient’s clinical manifestations, laboratory results of B cell lymphocytosis, and genetic findings, a diagnosis of atypical BENTA was considered. The NF-κB family of transcription factors plays a crucial role in inflammation, immunity, and cell proliferation (5, 21). CARD11 is expressed mainly in lymphocytes and is a large scaffold protein bridging the AgR of B or T cells with several signaling pathways, including NF-κB (22). GOF mutants in the CARD11 gene result in the spontaneous assembly of the CARD11-BCL10-MALT1 complex, which drives constitutive activation of NF-κB (23). Somatic K344del mutation was reported in one patient with diffuse large B-cell lymphoma (24), and to our knowledge, this variant has not been reported to be inherited (germline). To investigate the effects of K344del, we expressed the mutant and wild-type constructs along with a positive control (C49Y) in HCT116. Our findings showed that the K344del variant resulted in the aggregation of CARD11 and increased activation of NF-κB, consistent with previous studies on GOF mutations in the CARD11 gene (16). Besides the GOF effect, CARD11 could lead to a dominant negative effect, involving immunodeficiency with atopic dermatitis. We noted that affected members in a four-generation family with a novel heterozygous germline mutation (c.701-713delinsT, p.H234Ldel235-8) in CARD11 exhibited “mixed” clinical manifestations of BENTA (milder to moderate B cell lymphocytosis) with atopic dermatitis, which is consistent with both the GOF and dominant negative signaling effects (11). To investigate if the K344del CARD11 has a dominant negative effect, indicated by decreased activity in the heterozygous state compared with wild-type, plasmids with K344del CARD11 were co-transfected at a 1:1 ratio (or 4:1 ratio) with wild-type CARD11. We found that the NF-κB signaling pathway was also activated in the heterozygous state and K344del did not have a dominant negative effect. By reviewing the literature, a total of 23 patients were identified, and their clinical manifestations were highly heterogeneous. Previous studies reported that patients with G123D, G123S, or G126D mutation had more severe symptoms, including B cell lymphocytosis, immunodeficiency, or death at a young age (13, 15, 16). Patients possessing the C49Y variant could present with recurrent fever and mild infection, and/or fatal hemophagocytic lymphohistiocytosis, and have a high risk for mortality at a young age (13, 19). It is clear that GOF mutation within CARD and LATCH domains is associated with severe phenotypes but more studies are needed for further confirmation. The heterogeneity of clinical phenotypes could be due to the potency of the GOF effect, additional genomic variants or modifications, and environmental factors. In addition, recurrent infection also affects CARD11 activity and disease severity. Lastly, the structural biology of the mutant CARD11 within the CARD11-BCL10-MALT1(CBM) signalosome complex may be another factor to mediate the CARD11 activity. This in turn, affects clinical symptoms and needs further study. For the patients with BENTA that survive to adulthood, as B cell lymphocytosis gets milder with aging (14), it is likely that patients are clinically asymptomatic, like the mother of our patient, and could be missed. Polyclonal expansion of B cells is a hallmark of BENTA and polyclonal expansion of B cells increases the risk of B cell malignancy later in life. In addition, BENTA patients also have recurrent infections, including Epstein–Barr virus (EBV) infections. Impaired control of EBV infection has emerged as a recurring problem in BENTA disease (18, 25). A previous study demonstrated that the control of viral infection was inadequate, especially of chronic, low-grade EBV viremia, and the presence of EBV viremia may also increase the risk of B cell lymphomagenesis (26). Therefore, BENTA patients should be regularly monitored for B cell clonal expansion and infection, even EBV viral load. There are some limitations in our study. Due to the difficulty in obtaining specimens from the patient and his mother, an experiment to examine the NF-κB activity and cellular distribution of CARD11 was not done. In addition, the clinical laboratory examination regarding the presence or absence of B cell expansion was missing. Finally, in vitro functional study on the mutant CARD11 was performed in HCT116 cells but not in lymphocyte cell lines, even though the expression level of CARD11 was low in HCT116 cells ( ), which can reduce background interference. In conclusion, we reported a germline heterozygous GOF variant in the CARD11 gene from a patient with B cell lymphocytosis and constitutive NF-κB activation. Our study provides functional evidence of the pathogenicity of this mutation. The literature review indicates that the clinical manifestations of BENTA patients are highly heterogeneous. Additional basic research focusing on the CARD11 signal and the balance of CARD11 activity will help determine the factors that influence BENTA pathogenesis.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: SRA PRJNA855490, ClinVar SCV002564141.1.

Ethics statement

The studies involving human participants were reviewed and approved by Institutional review board of Wuhan Children’s Hospital, Tongji Medical College, Huazhong University of Science & Technology. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

Author contributions

Study concepts: XH, YD. Study design: PZ, DS, QM, YD, XH. Literature reserch: QM, PZ, YH. Clinical information collection: DS, QM, YH. Data acquisition: QM, XZ, LZ, YZ, YH. Data analysis/interpretation: LZ, QM, XZ, LT. Manuscript preparation: XH, PZ. Manuscript editing: XH. Manuscript final version approval: YD. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by grants from the Wuhan Municipal Health Commission (NO.WX19C19) and the Youth Program of National Natural Science Foundation of China (NO.81700302).

Acknowledgments

We thank the patient for participating in this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
  26 in total

1.  A case of bad Carma!

Authors:  David Buchbinder; Aaron Sassoon
Journal:  Blood       Date:  2017-03-23       Impact factor: 22.113

Review 2.  Lymphocyte signaling and activation by the CARMA1-BCL10-MALT1 signalosome.

Authors:  Isabel Meininger; Daniel Krappmann
Journal:  Biol Chem       Date:  2016-12-01       Impact factor: 3.915

Review 3.  NF-κB and the link between inflammation and cancer.

Authors:  Joseph A DiDonato; Frank Mercurio; Michael Karin
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

Review 4.  The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes.

Authors:  David J Rawlings; Karen Sommer; Miguel E Moreno-García
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

5.  Whole-exome sequencing links caspase recruitment domain 11 (CARD11) inactivation to severe combined immunodeficiency.

Authors:  Johann Greil; Tobias Rausch; Thomas Giese; Obul R Bandapalli; Volker Daniel; Isabelle Bekeredjian-Ding; Adrian M Stütz; Christoph Drees; Susanne Roth; Jürgen Ruland; Jan O Korbel; Andreas E Kulozik
Journal:  J Allergy Clin Immunol       Date:  2013-04-03       Impact factor: 10.793

6.  Mild B-cell lymphocytosis in patients with a CARD11 C49Y mutation.

Authors:  David Buchbinder; Jeffrey R Stinson; Diane J Nugent; Lucie Heurtier; Felipe Suarez; Gauthaman Sukumar; Clifton L Dalgard; Cécile Masson; Mélanie Parisot; Yu Zhang; Helen F Matthews; Helen C Su; Anne Durandy; Alain Fischer; Sven Kracker; Andrew L Snow
Journal:  J Allergy Clin Immunol       Date:  2015-04-28       Impact factor: 10.793

Review 7.  Pathologically Relevant Mouse Models for Epstein-Barr Virus-Associated B Cell Lymphoma.

Authors:  Shiyu Huang; Tomoharu Yasuda
Journal:  Front Immunol       Date:  2021-02-24       Impact factor: 7.561

8.  The First Case of BENTA Disease (B Cell Expansion with NF-κB and T Cell Anergy) from Iran.

Authors:  Maryam Neishabury; Azita Azarkeivan; Maghsood Mehri; Hossein Najmabadi; Taher Cheraghi
Journal:  J Clin Immunol       Date:  2021-01-13       Impact factor: 8.317

Review 9.  The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases.

Authors:  Mohammad Reza Zinatizadeh; Bettina Schock; Ghanbar Mahmoodi Chalbatani; Peyman Kheirandish Zarandi; Seyed Amir Jalali; Seyed Rouhollah Miri
Journal:  Genes Dis       Date:  2020-07-18

Review 10.  The CARD11-BCL10-MALT1 (CBM) signalosome complex: Stepping into the limelight of human primary immunodeficiency.

Authors:  Stuart E Turvey; Anne Durandy; Alain Fischer; Shan-Yu Fung; Raif S Geha; Andreas Gewies; Thomas Giese; Johann Greil; Bärbel Keller; Margaret L McKinnon; Bénédicte Neven; Jacob Rozmus; Jürgen Ruland; Andrew L Snow; Polina Stepensky; Klaus Warnatz
Journal:  J Allergy Clin Immunol       Date:  2014-08       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.